TY  - CONF
AU  - Petrović, Tamara
AU  - Gligorijević, Nevenka
AU  - Belaj, Ferdinand
AU  - Grgurić-Šipka, Sanja
AU  - Nikolić, Stefan
AU  - Krstić, Milena
AU  - Poljarević, Jelena
AU  - Mihajlović-Lalić, Ljiljana E.
PY  - 2022
UR  - https://vet-erinar.vet.bg.ac.rs/handle/123456789/2798
AB  - Rhenium complexes merit particular attention in the area of metallodrug design due to rhenium’s broad spectrum of oxidation states and consequently, the possibility to design compounds of a great structural diversity. Thus, the synthesis, chemical characterization and antitumor activity in vitro of the three Re(V) complexes is described. Novel compounds were obtained via reaction of [ReOCl3(PPh3)2] with corresponding ligands (pyridine-2-carboxylic acid, 3-methylpyridine-2-carboxylic acid and 6-methylpyridine- 2-carboxylic acid) in acetonitrile at 78 °C for 3h. The complexes were fully characterized using NMR, IR, MS and elemental analysis. Their octahedral geometry with bidentate N^O ligand was confirmed by X-ray diffraction analysis. Antiproliferative effect was determined by MTT assay and only the complex with pyridine-2-carboxylic acid (1) showed dose-dependent cytotoxic potential, particularly toward triple-negative breast adenocarcinoma cells MDA-MB-231 with IC50 68.90 ±
1.73 μM and pancreatic adenocarcinoma cells PANC-1 with IC50 69.8 ± 2.3 μM. Drug combination studies in PANC-1 cells with 1 and Verapamil hydrochloride (VRP) showed slight arrest of cell cycle in the S phase and also it increase its antiproliferative potential to IC50 51.4 ± 2.8 μM. Part of the research included a depletion of the glutathione (GSH) level by L-buthionine-sulfoximine (L-BSO) at sub-toxic concentrations (100 μM) in PANC-1 cells which caused an increase of activity of 1 to the IC50 57.67 ± 6.51 μM.
C3  - Osterreichische Chemietage, Wienna, Austria, September 20-22, 2022
T1  - Oxorhenium(V) complexes in the drug combination study
SP  - 90
EP  - 90
UR  - https://hdl.handle.net/21.15107/rcub_veterinar_2798
ER  - 

@conference{
author = "Petrović, Tamara and Gligorijević, Nevenka and Belaj, Ferdinand and Grgurić-Šipka, Sanja and Nikolić, Stefan and Krstić, Milena and Poljarević, Jelena and Mihajlović-Lalić, Ljiljana E.",
year = "2022",
abstract = "Rhenium complexes merit particular attention in the area of metallodrug design due to rhenium’s broad spectrum of oxidation states and consequently, the possibility to design compounds of a great structural diversity. Thus, the synthesis, chemical characterization and antitumor activity in vitro of the three Re(V) complexes is described. Novel compounds were obtained via reaction of [ReOCl3(PPh3)2] with corresponding ligands (pyridine-2-carboxylic acid, 3-methylpyridine-2-carboxylic acid and 6-methylpyridine- 2-carboxylic acid) in acetonitrile at 78 °C for 3h. The complexes were fully characterized using NMR, IR, MS and elemental analysis. Their octahedral geometry with bidentate N^O ligand was confirmed by X-ray diffraction analysis. Antiproliferative effect was determined by MTT assay and only the complex with pyridine-2-carboxylic acid (1) showed dose-dependent cytotoxic potential, particularly toward triple-negative breast adenocarcinoma cells MDA-MB-231 with IC50 68.90 ±
1.73 μM and pancreatic adenocarcinoma cells PANC-1 with IC50 69.8 ± 2.3 μM. Drug combination studies in PANC-1 cells with 1 and Verapamil hydrochloride (VRP) showed slight arrest of cell cycle in the S phase and also it increase its antiproliferative potential to IC50 51.4 ± 2.8 μM. Part of the research included a depletion of the glutathione (GSH) level by L-buthionine-sulfoximine (L-BSO) at sub-toxic concentrations (100 μM) in PANC-1 cells which caused an increase of activity of 1 to the IC50 57.67 ± 6.51 μM.",
journal = "Osterreichische Chemietage, Wienna, Austria, September 20-22, 2022",
title = "Oxorhenium(V) complexes in the drug combination study",
pages = "90-90",
url = "https://hdl.handle.net/21.15107/rcub_veterinar_2798"
}

Petrović, T., Gligorijević, N., Belaj, F., Grgurić-Šipka, S., Nikolić, S., Krstić, M., Poljarević, J.,& Mihajlović-Lalić, L. E.. (2022). Oxorhenium(V) complexes in the drug combination study. in Osterreichische Chemietage, Wienna, Austria, September 20-22, 2022, 90-90.
https://hdl.handle.net/21.15107/rcub_veterinar_2798

Petrović T, Gligorijević N, Belaj F, Grgurić-Šipka S, Nikolić S, Krstić M, Poljarević J, Mihajlović-Lalić LE. Oxorhenium(V) complexes in the drug combination study. in Osterreichische Chemietage, Wienna, Austria, September 20-22, 2022. 2022;:90-90.
https://hdl.handle.net/21.15107/rcub_veterinar_2798 .

Petrović, Tamara, Gligorijević, Nevenka, Belaj, Ferdinand, Grgurić-Šipka, Sanja, Nikolić, Stefan, Krstić, Milena, Poljarević, Jelena, Mihajlović-Lalić, Ljiljana E., "Oxorhenium(V) complexes in the drug combination study" in Osterreichische Chemietage, Wienna, Austria, September 20-22, 2022 (2022):90-90,
https://hdl.handle.net/21.15107/rcub_veterinar_2798 .